STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ) today announces that its subsidiary Dosell AB has been granted a European patent, EP4228584, titled "Medication Delivery". The patent strengthens iZafe Group's long-term position within data-driven and personalized healthcare and represents an important part of the company's continued development of digital care solutions, including its new remote care system.
The patent covers a system where patient data from sensors is analyzed to identify changes in health status. Based on this information, medication treatment can be adjusted over time, enabling more personalized and proactive care.
Although the patent is not directly linked to Dosell's current functionality, it aligns with iZafe Group's strategic direction of combining medical technology, data, and future AI-based analytics.
Through this patent, the company strengthens:
its technological platform for future solutions
its intellectual property value
its position within a growing global healthcare segment
In the long term, the technology enables solutions where treatment can be optimized based on real patient data, contributing to improved patient safety and more efficient healthcare.
"This patent is an important step in our long-term strategy. It clearly demonstrates the direction we are moving in-towards more data-driven, intelligent, and personalized healthcare. At the same time, it strengthens our intellectual property and future potential," says Anders Segerström, CEO of iZafe Group.
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company's Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com
Image Attachments
Dosell Distansvårdssystem
Attachments
Dosell AB Granted European Patent in Data-Driven Medication Management
SOURCE: iZafe Group
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dosell-ab-granted-european-patent-in-data-driven-medication-managemen-1154174
